Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P13647: Variant p.Ala428Thr

Keratin, type II cytoskeletal 5
Gene: KRT5
Feedback?
Variant information Variant position: help 428 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Alanine (A) to Threonine (T) at position 428 (A428T, p.Ala428Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and hydrophobic (A) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In EBS2C. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 428 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 590 The length of the canonical sequence.
Location on the sequence: help ANLQNAIADAEQRGELALKD A RNKLAELEEALQKAKQDMAR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 590 Keratin, type II cytoskeletal 5
Domain 168 – 481 IF rod
Region 339 – 477 Coil 2
Site 419 – 419 Stutter
Mutagenesis 411 – 411 Q -> A. No effect on interaction with KRT14 or keratin intermediate filament networks.
Mutagenesis 412 – 412 N -> A. No effect on interaction with KRT14 or keratin intermediate filament networks.
Mutagenesis 422 – 422 E -> A. No effect on interaction with KRT14 or keratin intermediate filament networks.
Mutagenesis 437 – 437 E -> A. No effect on interaction with KRT14 or keratin intermediate filament networks.
Mutagenesis 440 – 440 Q -> A. No effect on interaction with KRT14 or keratin intermediate filament networks.
Mutagenesis 444 – 444 Q -> A. No effect on interaction with KRT14 or keratin intermediate filament networks.
Helix 384 – 474



Literature citations
Two novel recessive mutations in KRT14 identified in a cohort of 21 Spanish families with epidermolysis bullosa simplex.
Garcia M.; Santiago J.L.; Terron A.; Hernandez-Martin A.; Vicente A.; Fortuny C.; De Lucas R.; Lopez J.C.; Cuadrado-Corrales N.; Holguin A.; Illera N.; Duarte B.; Sanchez-Jimeno C.; Llames S.; Garcia E.; Ayuso C.; Martinez-Santamaria L.; Castiglia D.; De Luca N.; Torrelo A.; Mechan D.; Baty D.; Zambruno G.; Escamez M.J.; Del Rio M.;
Br. J. Dermatol. 165:683-692(2011)
Cited for: VARIANTS EBS2C GLU-186; LYS-193; PRO-321; VAL-328 AND THR-428; VARIANTS EBS2A SER-165 AND LYS-477; VARIANT EBS2F LEU-25; VARIANT EBS2B PRO-463;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.